KR890002230A - 항생물질 a40926 만노실 아글리콘 - Google Patents

항생물질 a40926 만노실 아글리콘 Download PDF

Info

Publication number
KR890002230A
KR890002230A KR1019870006803A KR870006803A KR890002230A KR 890002230 A KR890002230 A KR 890002230A KR 1019870006803 A KR1019870006803 A KR 1019870006803A KR 870006803 A KR870006803 A KR 870006803A KR 890002230 A KR890002230 A KR 890002230A
Authority
KR
South Korea
Prior art keywords
antibiotic
addition salts
newsol
ppm
mannosyl
Prior art date
Application number
KR1019870006803A
Other languages
English (en)
Other versions
KR960010556B1 (ko
Inventor
셀바 엔리코
페 라리 피에트로
피. 골트스테인 베드
피.골트스테인 베드
파렌티 프란체스코
카싸니 지오반니
Original Assignee
그루포 레페티트 에스. 피. 에이.
레나토 스가르비
그루포 레Vp티트 에스. 피. 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그루포 레페티트 에스. 피. 에이., 레나토 스가르비, 그루포 레Vp티트 에스. 피. 에이 filed Critical 그루포 레페티트 에스. 피. 에이.
Publication of KR890002230A publication Critical patent/KR890002230A/ko
Application granted granted Critical
Publication of KR960010556B1 publication Critical patent/KR960010556B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/19—Antibiotic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음

Description

항생물질 A40926 만노실 아글리콘
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 항생물질 A 40926 만노실 아글리콘의 U.V.스팩트럼을 나타낸 것임.
제2도는 항생물질 A 40926 만노실 아글리콘의 1.R.스팩트럼을 나타낸 것임.
제3도는 항생물질 A 40926 만노실 아글리콘의 1H-N.M.R스팩트럼을 나타낸 것임.

Claims (5)

  1. 다음과 같은 특성을 갖는 비 부가염 형태의 항생물질 A 40926 만노실 아글리콘 및 그의 부가염.
    A) 다음과 같은 최대치를 나타내는 자외선 흡수 스펙트럼
    B) 다음과 같은 흡수 최대치(㎝-1)를 나타내는 적외선 흡수 스팩트럼 3700-3100; 3000-2800(뉴졸); 1655; 1620-1540; 1505; 1460(뉴졸); 1375(뉴졸) 1350-1250; 1210; 1150; 1020; 970; 850,810
    C) DMSO d6(헥사듀테로디메틸술폭시드)+CH3COOH중에서 내부 표준 (0.00ppm)으로서 TMS를 사용하여 기록했을 때 270MHZ에서 다음과 같은 시그날 (ppm)군을 나타내는 1H-NMR스팩트럼(δ=ppm, 다중도, 속성)
    2.51,s(DMSOds); 2.50, S(NCH2), 2.88, m(Z2); 3.30, m(Z′2); 4.08, m(X6); 4.44, d(X5); 4.49 d(X7); 4.83, m(X2); 5.02, S(4F); 5.08, S(Z6); 5.31, S(만노스의 아노머 양성자); 5.53, d(X4); 5.78, S(4B); 6.08, d(X3); 7.70, S(6B); 6.44-8.52(방향족 및 팹티드의 NH들)
    D) 다음과 같은 조건하에서, 역상 HPLC에 의해 분석했을 때 항생물질 L 17054(TA 3-1) (Rt=8.78분)에 대한 체류시간 (RT)이 1.18임 컬럼: Ultraspere ODS(5μ m)Aletx(벡크만산 제품)4.6mm(내경)X250㎜
    예비 컬럼: Brownlee Labs. RP 18(5μm)
    용출: 용출제 A중에서 5 내지 60%의 용출제 B 선형 구배로 40분 이내에 용출시킴.
    유속: 1.6 ml/분
    U.V. 검출기; 254㎜
    내부표준: 항생물질 L 17054(TA 3-1)(그루포레페티드 에스.피.에스.제품)
    E) 다음과 같은 크로마토그래피 시스템에서 Rf값이 0.39임.
    NaH2PO4H2O를 1당 5g 함유하는
    PH를 6.0으로 조절하고, 실란화 Silica gel 60 F254Merck 플레이트(층 두께 0.25㎜)를 사용하였음.
    가시화: -자외선 -포올리 시약, 즉 디아조화 술파닐산[J. Chromatog. 제20호, 제171페이지(1965년) 및 Z. Physiol. chem, 제292호, 제99페이지(1953년)참조]을 사용했을 때 황색-최소 데이비스 배지에서 고초균 ATCC 6633을 사용하는 바이오토그래피.
    F) 약 1374에서를 갖는 견뢰 원자 충경(FAB)질량 스펙트럼.
  2. 다음과 같은 일반식을 갖는 비-부가염 형태의 항생물질 A 40926 만노실 아글리콘 및 그의 산 부가염.
    상기식중 A는 수소이고, B는 만노실기이다.
  3. 의약품으로서의 용도의 제1항 또는 제2항에 의한 화합물.
  4. 제1항 또는 제2항에 의한 화합물의 향균 치료용 의약품 제조 용도.
  5. 제1항 또는 제2항에 의한 화합물과 제약상 허용되는 담체로 되는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870006803A 1985-12-30 1987-07-01 항생물질 a 40926 만노실 아글리콘 KR960010556B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8531846 1985-12-30
GB858531846A GB8531846D0 (en) 1985-12-30 1985-12-30 Antibiotic a 40926 mannosyl aglycon

Publications (2)

Publication Number Publication Date
KR890002230A true KR890002230A (ko) 1989-04-08
KR960010556B1 KR960010556B1 (ko) 1996-08-02

Family

ID=10590309

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019860011487A KR950010460B1 (ko) 1985-12-30 1986-12-29 항생 물질 a40926 만노실 아글리콘의 제조방법
KR1019870006803A KR960010556B1 (ko) 1985-12-30 1987-07-01 항생물질 a 40926 만노실 아글리콘

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019860011487A KR950010460B1 (ko) 1985-12-30 1986-12-29 항생 물질 a40926 만노실 아글리콘의 제조방법

Country Status (14)

Country Link
US (1) US4782042A (ko)
EP (1) EP0228015B1 (ko)
JP (1) JP2514942B2 (ko)
KR (2) KR950010460B1 (ko)
AT (1) ATE71113T1 (ko)
DE (1) DE3683266D1 (ko)
DK (1) DK167815B1 (ko)
ES (1) ES2038593T3 (ko)
GB (1) GB8531846D0 (ko)
GR (1) GR3003514T3 (ko)
HU (1) HU201099B (ko)
IE (1) IE59603B1 (ko)
IL (1) IL81105A (ko)
ZA (1) ZA869716B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK363587A (da) * 1986-07-30 1988-01-31 Smithkline Beckman Corp Antibiotika og fremstilling heraf under anvendelseaf actinomadura parvosata
GB8621912D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) * 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
DE68925951T2 (de) * 1988-12-27 1996-07-25 Lepetit Spa Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze
US5206834A (en) * 1989-10-14 1993-04-27 Mitsubishi Denki Kabushiki Kaisha Semiconductor memory device performing last in-first out operation and the method for controlling the same
DE69012942T2 (de) * 1989-10-16 1995-03-02 Lilly Co Eli Glycopeptid-Antibiotika.
US5224972A (en) * 1990-09-11 1993-07-06 Frye Gregory C Coatings with controlled porosity and chemical properties
HUT63860A (en) * 1990-12-05 1993-10-28 Lepetit Spa Process for producing 39-decarboxy-38-(hydroxymethyl) derivatives of teikoplanin antibiotics
HU210665B (en) 1991-03-27 1995-06-28 Lepetit Spa Process for producing ester derivatives of the antibiotic a 40926 and pharmaceutical compositions containing them as active component
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
CN1036654C (zh) * 1993-01-01 1997-12-10 格鲁波莱佩蒂特公司 抗菌素a40926的酰氨衍生物及其制备方法
AU701463B2 (en) * 1995-07-05 1999-01-28 Sanofi Aventis S.P.A. Purification of dalbaheptide antibiotics by isoelectric focusing
CA2250578C (en) 1996-04-23 2003-06-24 Versicor Inc. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20050090433A1 (en) * 2002-11-18 2005-04-28 Vicuron Pharmaceuticals, Inc Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
JP5852880B2 (ja) * 2011-12-28 2016-02-03 国立研究開発法人国立循環器病研究センター 温度感応性材料
WO2020222100A1 (en) * 2019-04-30 2020-11-05 Actygea S.R.L. Method for the purification of lipoglycopeptide antibiotics
KR102467772B1 (ko) 2022-08-23 2022-11-16 최세근 디자인에 따라 결합 가능한 모듈이 구비된 신발

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521335A (en) * 1983-07-13 1985-06-04 Smithkline Beckman Corporation Aglycone and pseudo-aglycones of the AAD 216 antibiotics
GB8425685D0 (en) * 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex

Also Published As

Publication number Publication date
HU201099B (en) 1990-09-28
GB8531846D0 (en) 1986-02-05
IL81105A0 (en) 1987-03-31
DK617086A (da) 1987-07-01
IE59603B1 (en) 1994-03-09
US4782042A (en) 1988-11-01
JPS62175499A (ja) 1987-08-01
ATE71113T1 (de) 1992-01-15
ZA869716B (en) 1987-10-28
KR960010556B1 (ko) 1996-08-02
EP0228015A2 (en) 1987-07-08
DK167815B1 (da) 1993-12-20
IE863381L (en) 1987-06-30
DK617086D0 (da) 1986-12-19
ES2038593T3 (es) 1993-08-01
GR3003514T3 (ko) 1993-03-16
HUT43091A (en) 1987-09-28
KR950010460B1 (ko) 1995-09-18
JP2514942B2 (ja) 1996-07-10
EP0228015A3 (en) 1987-12-16
KR870006193A (ko) 1987-07-09
EP0228015B1 (en) 1992-01-02
IL81105A (en) 1991-09-16
DE3683266D1 (de) 1992-02-13

Similar Documents

Publication Publication Date Title
KR890002230A (ko) 항생물질 a40926 만노실 아글리콘
Dürckheimer Tetracyclines: chemistry, biochemistry, and structure‐activity relations
Ruff-Jamison et al. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver.
RU94036004A (ru) Промежуточные соединения для получения ароматических аминоспиртовых производных
Takai et al. Usnic acid derivatives as potential antineoplastic agents
Blackwood et al. Structure–activity relationships in the tetracycline series
Boppana et al. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography
FR2662440B1 (fr) Procede de preparation stereoselective de derives de la phenylisoserine.
ITRM920919A1 (it) Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
DE69308029D1 (de) 1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8aBETA)-6-ISOCHINOLINAMINE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS THERAPEUTIKA
FI961914A0 (fi) Lyhytvaikutteiset dihydropyridiinit
NL8301980A (nl) Factoren 1,2,3,4, en 5 van teichomycine a2 en werkwijze voor de bereiding daarvan.
Wheeler et al. Use of high-pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration
Ohkubo et al. Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching
O'Keefe et al. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria
Hlavka et al. The tetracyclines
KR890002231A (ko) 항생물질 a40926 n-아실아미노글루쿠로닐 아글리콘 및 항생물질 a40926 아글리콘
RU94029667A (ru) ПРОИЗВОДНЫЕ 11β -БЕНЗАЛЬДОКСИМ-ЭСТРА-4,9-ДИЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
Chulasiri et al. Mutagenicity and antimutagenicity of hispidulin and hortensin, the flavonoids from Millingtonia hortensis L.
Ennis Structure-activity studies with cycloheximide and congeners
CA2071983A1 (fr) Derive de la beta-phenylisoserine, sa preparation et son emploi
Barrett Synthesis of tetracycline analogs
NO941676L (no) Polycykliske forbindelser og fremgangsmåter for fremstilling av dem
KR930004471A (ko) 항생 물질 GE 2270 인자 C₂ａ
ATE23719T1 (de) Rifamycinderivate, herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee